Eli Lilly: FDA approves treatment for eczema

(CercleFinance.com) - The Group announces that the FDA has approved Lilly's EBGLYSS (lebrikizumab-lbkz) for adults and children aged 12 and over with moderate to severe atopic dermatitis.


Approval was based on the results of the ADvocate 1, ADvocate 2 and ADhere studies, which involved more than 1,000 adults and children (aged 12 and over) with moderate-to-severe eczema who were unable to control their symptoms with topical prescription medications.

Patients treated with EBGLYSS experienced significant skin clearing as early as four weeks, and significant itch relief as early as two weeks.

' Patients still struggle to control their moderate to severe atopic dermatitis with currently available treatments. Many suffer from poor long-term disease control, and severe itching can have a significant impact on their daily lives,' said Jonathan Silverberg, M.D., Ph.D., M.P.H., Professor of Dermatology at the George Washington University School of Medicine and Health Sciences in Washington, DC.

' Today's FDA approval of EBGLYSS is a great victory for patients, as we now have a new first-line biologic treatment option for moderate to severe disease when topical prescriptions are not sufficient. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.